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Preventing Unintended Pregnancy and HIV Transmission:
Effects of the HIV Treatment Cascade on Contraceptive
Use and Choice in Rural KwaZulu-Natal
Julia Raifman, SM,*† Terusha Chetty, FCPHM, MBChB, DCH, MMed,† Frank Tanser, PhD,†
Tinofa Mutevedzi, MSc,† Philippa Matthews, MBBS, DCH, FRCGP,†
Kobus Herbst, MBChB, MSc, FFCH,† Deenan Pillay, MBBS, PhD,†‡
and Till Bärnighausen, MD, ScD*†
Background: For women living with HIV, contraception using
condoms is recommended because it prevents not only unintended
pregnancy but also acquisition of other sexually transmitted
infections and onward transmission of HIV. Dual-method dual-
protection contraception (condoms with other contraceptive meth-
ods) is preferable over single-method dual-protection contraception
(condoms alone) because of its higher contraceptive effectiveness.
We estimate the effect of progression through the HIV treatment
cascade on contraceptive use and choice among HIV-infected
w o m e ni nr u r a lS o u t hA f r i c a .
Methods: We linked population-based surveillance data on contra-
ception collected by the Wellcome Trust Africa Centre for Health and
Population Studies to data from the local antiretroviral treatment
(ART) program in Hlabisa subdistrict, KwaZulu-Natal. In bivariate
probit regression, we estimated the effects of progressing through the
cascade on contraceptive choice among HIV-infected sexually active
women aged 15–49 years (N = 3169), controlling for a wide range of
potential confounders.
Findings: Contraception use increased across the cascade from ,40%
among HIV-infected women who did not know their status to .70%
among women who have been on ART for 4–7y e a r s .H o l d i n go t h e r
factors equal (1) awareness of HIV status, (2) ART initiation, and (3)
being on ART for 4–7 years increased the likelihood of single-method/
dual-method dual protection by the following percentage points (pp),
compared with women who were unaware of their HIV status: (1) 4.6
pp (P = 0.030)/3.5 pp (P =0 . 0 0 1 ) ,( 2 )1 0 . 3p p( P = 0.003)/5.2 pp (P =
0.007), and (3) 21.6 pp (P , 0.001)/11.2 pp (P , 0.001).
Conclusions: Progression through the HIV treatment cascade
signiﬁcantly increased the likelihood of contraception in general
and contraception with condoms in particular. ART programs are
likely to contribute to HIV prevention through the behavioral
pathway of changing contraception use and choice.
Key Words: unintended pregnancy, HIV, AIDS, reproductive
health, contraception, condoms, HIV transmission
(J Acquir Immune Deﬁc Syndr 2014;67:S218–S227)
INTRODUCTION
All women have the reproductive health rights “to decide
freely and responsibly on the number and spacing of their chil-
dren and to have access to the information, education, and
means to enable them to exercise these rights.”
1 For all women,
the ability to freely choose the method of contraception that best
fulﬁlls her individual reproductive health needs and wants is an
essential component of these rights.
2 Among women living
with HIV, prevention of unintended pregnancy is an effective
approach to prevent mother-to-child transmission of the virus.
3
In making contraceptive choices, women living with HIV have
to consider a number of risks that are different from those that
HIV-uninfected women are facing. Compared with HIV-
uninfected women, HIV-infected women are at greater risk of
morbidity and mortality during pregnancy and motherhood
4 and
are at increased risk of severe illness from sexually transmitted
infections (STIs) other than HIV.
5–7 HIV-infected women also
face the risk of superinfection with a second strain of HIV,
which may cause more rapid disease progression and limit
treatment options.
8,9 Finally, women living with HIV are at risk
of transmitting HIV to their uninfected partners.
Male and female condoms can provide dual protection
against unintended pregnancy as well as acquisition and
transmission of STIs, including HIV. Other methods of
contraception, such as oral and injectable contraceptive drugs
and male or female sterilization can prevent unintended
pregnancy but do not serve the additional purpose of
protecting against STI acquisition and transmission. Although
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ception using both condoms and another method is more
effective for preventing unintended pregnancies than condom
use alone.
In the following, we will use the term single-method
dual protection to indicate condom use alone and dual-
method dual protection to indicate concurrent use of condoms
and at least one other contraceptive method. We will use the
term single protection to indicate contraception without
condoms. Although women who are HIV infected can use
all of the same contraceptive methods as women who are HIV
uninfected, WHO recommends that HIV-infected women use
dual protection, and ideally dual-method dual protection to
maximize effectiveness in preventing both pregnancy and STI
acquisition and transmission.
10
The large-scale use of antiretroviral treatment (ART) has
changed what it means to live with HIV and to live in one of the
communities in sub-Saharan Africa that are severely affected by
the HIV epidemic.
11 ART substantially reduces HIV-related
mortality
12 and can dramatically improve life expectancy in
communities with high HIV prevalence.
11 By reducing the con-
centration of HIV in body ﬂuids, ART can also substantially
decrease the risk of HIV transmission from an infected to an
uninfected partner.
13 Although these biological effects of anti-
retroviral medication are well established, our knowledge of the
behavioral effects of ART programs is limited.
The HIV patient pathway from infection to long-term
treatment, the “HIV treatment cascade,”
14 can be divided into
several steps. First, an HIV-infected woman learns about her
positive HIV status in an HIV testing and counseling session,
which typically conveys information about HIV infection,
options for long-term care and treatment, the importance of
disclosure of HIV status to family members and sexual part-
ners, as well as approaches to prevent onward transmission of
HIV.
15 Next, the HIV-infected woman can enroll in pre-ART
programs for regular review of ART eligibility, prevention of
opportunistic infections, contraceptive counseling, and coun-
seling to prevent onward transmission of HIV.
16–18 At some
point after becoming eligible for HIV treatment, the HIV-
infected woman may initiate ART; ART initiation is usually
preceded by treatment education including information on the
importance of ART adherence, disclosure, and practicing safe
sex behaviors.
19 Finally, as the HIV-infected woman remains
enrolled in the ART program, she will regularly visit ART
clinics for assessment of treatment success and continued coun-
seling, including on contraception and prevention of HIV trans-
mission. Progression through the HIV treatment cascade is thus
associated with ongoing counseling and knowledge gain on
contraceptive choices for HIV-infected women and prevention
of HIV transmission. Additionally, the repeated interactions
with the health system along the cascade can imply access to
contraceptive methods. HIV testing and counseling centers and
ART clinics commonly provide male and female condoms, and
they are often located close to other health care facilities, such
as primary care clinics and family planning centers,
20 where
contraceptive methods are available. It is thus plausible that
HIV-infected women will increasingly use contraception as
they advance from one stage in the cascade to the next. How-
ever, the type and magnitude of any such effects is unknown.
Here, we use a rare data opportunity—ART program data
that has been linked to population-based surveillance data—to
examine whether progression through the HIV treatment cas-
cade affected contraceptive use among the HIV-infected women
in a community in rural KwaZulu-Natal with high HIV preva-
lence
21 and incidence.
22 A previous study in the same commu-
nity found that ART coverage of HIV-infected populations
protected HIV-uninfected individuals from acquiring HIV.
23 In
addition to the biological effect of ART, one of the potential
causal mechanisms underlying this effect of ART coverage on
HIV acquisition could be effects of the ART scale-up on dual
protection. To elucidate this possible behavioral pathway from
ART scale-up to HIV incidence, we estimate the effects of pro-
gression through the HIV treatment cascade on single- and dual-
protection contraception.
METHODOLOGY
Setting and Data Collection
We use data collected by the Wellcome Trust Africa
Centre for Health and Population Studies (Africa Centre).
Since 2000, the Africa Centre has operated a longitudinal
Health and Demographic Surveillance System, covering the
entire population living in a 438 km2 surveillance area (about
100,000 individuals) in the rural uMkhanyakude district in
northern KwaZulu-Natal, South Africa.
24 HIV prevalence in
the adult population in this community was 29% in 2011
21
and incidence has been around 3 per 100 person-years for the
last decade,
22 with a slight decline in recent years.
23 ART
coverage of all HIV-infected adults in the community has
risen from 0% in 2003 to 31% in 2011.
21 The surveillance
includes longitudinally linked annual HIV testing but the HIV
test results are not provided to the surveillance participants.
The people living in the surveillance area can test for HIV
free of charge at public-sector HIV testing and counseling
centers and primary care clinics. They can also test for HIV
in private-sector physician practices and pharmacies. During
the individual surveillance interviews, all respondents are
asked whether they know their HIV status and all women
are asked about their contraceptive use. The surveillance also
includes linked longitudinal data on demographic, social, and
economic factors. To determine progression through the HIV
treatment cascade, we linked the data on clinic visits and ART
initiation collected in the local public-sector ART program to
the population-based surveillance data, using the South Afri-
can identiﬁcation number, ﬁrst name, last name, and birth
dates for linkage.
25
In 2004, the South African Department of Health in
collaboration with the Africa Centre started the Hlabisa HIV
Treatment and Care Programme with support from the
Presidential Emergency Fund for AIDS Relief (PEPFAR).
The program delivers ART through the 17 public-sector
primary care clinics in Hlabisa subdistrict. The program
provides free HIV testing and counseling, ART, and male and
female condoms; it also includes an active pre-ART compo-
nent enrolling patients for ongoing counseling and monitoring
of CD4 count, HIV disease progression, and health status to
determine ART eligibility. Before ART initiation, all patients
participate in three group sessions and individual counseling.
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program to see a nurse and a counselor and to participate in
group and individual counseling sessions.
20 Because women
who intend to be pregnant or are “not on reliable contracep-
tion” should receive a different ﬁrst-line ART regimen than
other patients according to the South African national ART
guidelines,
18 contraception and fertility intentions should be
part of the conversation that health care providers have with
their ART patients during the monthly clinic visits.
Study Population
The study population included all women who met the
following eligibility criteria: they were of reproductive age
(15–49 years); they had either tested HIV positive in the
Africa Centre HIV surveillance or were enrolled in the Hla-
bisa HIV Treatment and Care Programme; they reported
being sexually active within the past year; and they reported
on their contraceptive use in the Women’s General Health
Survey. We used the latest report on contraceptive use avail-
able for each woman who met these eligibility criteria. We
used data beginning in 2005 because the Hlabisa HIV Treat-
ment and Care Programme started enrolling patients only at
the end of 2004.
20 We use data from the observation period
2005–2012.
Contraceptive Use Variables
Until 2009, the ﬁeld workers in the surveillance inquired
about contraceptive use in the individual interviews by asking
“Are you currently doing anything, or using any contraceptive
method, to delay or avoid getting pregnant?” If a woman
answered yes, interviewers asked her to specify which methods
she was using; the precoded answer options included the “pill,”
“intrauterine device,”“ Depo-Provera injection,”“ Nur-Isterate
injection,”“ male condom,”“ female condom,”“ female sterili-
zation,”“ male sterilization,” and “other.” The question
changed slightly in 2009. The surveillance interviewers now
asked “Have you ever used contraception?” Women who
answered yes were then asked “Which method are you cur-
rently using?” and could choose among the precoded answer
options: “none,”“ male condom,”“ female condom,”“ female
sterilization,”“ male sterilization,”“ injections,”“ pill,” and
“other.” One reason for this change in the question was that
TABLE 2. Distribution of Contraceptive Use
N( % )
No contraception 1468 (46)
Single protection 729 (17)
Injections 546 (17)
Pill 80 (3)
Female sterilization 95 (3)
Male sterilization 11 (0)
Single-method dual protection 777 (26)
Male condom only 741 (23)
Female condom only 29 (1)
Male condom and female condom 7 (,1)
Dual-method dual protection* 195 (6)
Male condom and injections 160 (3)
Male condom and pill 21 (1)
Male condom and female sterilization 6 (,1)
Male condom and male sterilization 2 (,1)
Female condom and injections 6 (,1)
Female condom and pill 1 (,1)
Female condom and female sterilization 0 (0)
Female condom and male sterilization 0 (0)
Sample size (N) 3169
*One individual was using more than 2 types of contraception.
TABLE 1. Sample Characteristics
Stage in the HIV treatment cascade
HIV+, unaware of HIV status 539 (17)
HIV+, awareness of HIV status unknown 292 (9)
HIV+, aware of HIV status 928 (29)
Pre-ART 708 (22)
0–1 years on ART 201 (6)
1–2 years on ART 163 (5)
2–4 years on ART 220 (7)
4–7 years on ART 118 (4)
Age 30.73 (7.80)
Education (in school grades attained) 10.58 (2.81)
Married or in a marriage-like relationship 795 (25)
Distance to nearest primary road, km 5.94 (6.31)
Distance to nearest secondary road, km 1.33 (1.11)
Pregnant at time of surveillance interview 133 (4)
Parity (number of births) 0.28 (0.98)
Health status
Poor 30 (1)
Fair 570 (18)
Good 262 (8)
Very good 2007 (63)
Excellent 300 (9)
Household wealth quintile
Poorest 654 (21)
Second 653 (21)
Third 660 (21)
Fourth 654 (21)
Richest 548 (17)
Calendar year
2005 249 (8)
2006 329 (11)
2007 316 (10)
2008 89 (3)
2009 282 (9)
2010 485 (15)
2011 741 (23)
2012 678 (21)
Sample size (N) 3169
For categorical variables–stage in the HIV treatment cascade, married or in
a marriage-like relationship, pregnant, health status, household wealth quintile, and
calendar year–the summary statistic shown here is the count of people that fall into
a category. The percentage of people in the category is shown in parentheses. For
continuous variables–age, education, distance to the nearest primary road, distance to
the nearest secondary road, and parity–the summary statistic shown here is the mean.
The standard deviation is shown in parentheses. Some of the percentages do not sum up
to 100% because the percentages for each category have been rounded to the nearest
integer. ART = antiretroviral treatment; km = kilometers; HIV+ = HIV-infected.
Raifman et al J Acquir Immune Deﬁc Syndr  Volume 67, Supplement 4, December 1, 2014
S220 | www.jaids.com  2014 Lippincott Williams & Wilkinshardly any women interviewed before 2009 had reported intra-
uterine device use. As deﬁned above, we categorized the
different contraceptive methods into single protection, single-
method dual-protection, and dual-method dual-protection
contraception (Table 2).
Explanatory Variables
We captured progression through the HIV treatment
cascade with dummy variables indicating knowledge of HIV
status, enrollment in pre-ART, and having received ART for
0–1, 1–2, 2–4, and 4–7 years. In addition, in the multivariable
regression analysis, we controlled for variables that have been
found to determine contraceptive use in other studies
26–28:
age, education, relationship status, parity, current pregnancy,
self-reported health status, the distance from a woman’s place
of residence to the nearest primary and the nearest secondary
road, household wealth, and calendar year. With the excep-
tion of the ART program data (pre-ART and time on ART),
all other information, including awareness of HIV status, was
collected by the Africa Centre surveillance. We used school
grade attainment data to capture education. We coded women
as being married or in a marriage-like relationship if she
reported that she was married, engaged, or cohabitating. We
coded age in years and included age squared to capture non-
linear age relationships with contraception use. Following
a previous study in this community,
29 we created wealth quin-
tiles based on the ranking of individuals on the ﬁrst principal
component obtained in a principal component analysis of
information on 27 household assets, such as vehicles, stoves,
beds, and livestock. We included the distances from a wom-
an’s place of residence to the nearest primary and the nearest
secondary road to capture geographical access to health care,
because car ownership is rare in this community and people
usually walk to the nearest road to fetch a mini bus to drive to
a health care facility.
30
Analysis
Our primary research question here was whether pro-
gression through the HIV treatment cascade affected single-
and dual-protection contraception. To answer this question,
we chose the bivariate probit model, because the two binary
decisions—whether or not to use single-protection contracep-
tion (ie, any contraceptive method except for condoms) and
whether or not to use single-method dual-protection contra-
ception (ie, condoms)—are likely dependent. We except
dependency of the two decisions based on both economic
theory (the two contraceptive approaches are imperfect sub-
stitutes) and the previous empirical literature.
31,32 In addition
to the bivariate probit regression coefﬁcients (Table 3), we
estimated average marginal effects (AMEs) for not using any
contraception, using single protection, using single-method
dual protection, and using dual-method dual protection
(Table 4). Conceptually, the AME for a dummy variable, such
as one of the variables representing a stage in the HIV treat-
ment cascade, is the average across all the individual marginal
effects for that dummy variable for each person in the data
set. These individual marginal effects are obtained by
computing each person’s probability of having the outcome
when the dummy variable is set to zero and when it is set to
unity, in both cases keeping the values of all the other explan-
atory variables to the values given for that person.
33 The
AMEs in Table 4 represent the change in the probability of
having the outcome when a certain stage of the cascade is
reached, compared to the stage that is the reference category.
The AME are shown in percentage points (pp). For instance,
a woman who has been on ART for 4–7 years is 21.6 pp more
likely to use single-method dual protection compared with an
HIV-infected woman who does not know her HIV status.
FINDINGS
There were 7443 HIV-infected women aged 15–49
years who participated in the Africa Centre Health and Demo-
graphic Surveillance between 2005 and 2012. Of these
women, 5510 (74.0%) reported on their sexual activity at
least once, and 4625 (83.9%) of the women who reported
on their sexual activity had been sexually active within the
past year. Among the 4625 women who had been sexually
active, data on all variables for the multiple regression anal-
ysis were available for 3169 (68.5%). Here, we present the
complete-case analyses of this sample of 3169 women.
Table 1 describes the characteristics of the 3169 women
in this sample. The majority of the HIV-infected women had
not yet enrolled in the ART program (55%). Among the
remaining women, half were enrolled in pre-ART and half
were on ART. More observations occurred in the latter half of
the observation period (68% in 2009–2012) than in the earlier
half (32% in 2005–2008). Table 2 shows the distribution of
contraceptive methods across the women in this sample of
sexually active HIV-infected women; 54% used contracep-
tion, and 32% used either single- or dual-method dual pro-
tection. Figure 1 shows descriptively contraceptive choice
through the HIV treatment cascade. Overall, contraceptive
use increased steadily across the stages of the cascade from
,40% among HIV-infected women who did not know their
status to .70% among women who had received ART for 4–
7 years. The increase in contraceptive use occurred largely
due to an increase in the use of dually protective methods.
These trends were even more pronounced when we
estimated the effect of progression through the HIV treatment
cascade on contraceptive use in bivariate probit analysis,
controlling for age, education, partnership status, pregnancy
status, parity, health status, household wealth, distance to
the nearest primary and secondary roads, and calendar year.
The coefﬁcient r, which measures the correlation between the
error terms of the two regressions that we jointly estimated in
the analysis, was negative (20.292) and highly signiﬁcant
(P , 0.0001). This correlation conﬁrms that the two contra-
ceptive choices should indeed be jointly estimated because of
a relationship between the choices that is not found in the
observed explanatory variables. Table 3 shows the regression
coefﬁcients and Table 4 the AME from this analysis. Compared
with HIV-infected women who were unaware of their positive
HIV status, the likelihood of single-method dual protection
increased by 4.6 pp when women became aware of their
HIV status (P = 0.030), by 10.3 pp when they initiated ART
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4–7y e a r s( P , 0.001). The likelihood of dual-method dual
protection increased by 3.5 pp when women became aware of
their HIV status (P = 0.001), by 5.2 pp when they initiated
ART (P =0 . 0 0 7 ) ,a n db y1 1 . 2p pw h e nt h e yh a dr e c e i v e d
ART for 4–7y e a r s( P , 0.001).
As robustness checks of the ﬁndings presented here, we
repeated the analyses with HIV-uninfected women also included
in the sample and after multiple imputation of missing covariates
a m o n gw o m e nw h or e p o r t e db e i n gs e x u a l l ya c t i v e .T h eﬁndings
from the analysis that includes HIV-negative women are
described in detail in the online Appendix (see Supplemental
Digital Content, http://links.lww.com/QAI/A576), including
the full tables with the descriptive statistics and the regression
results. This additional analysis has several advantages (large
sample size, ability to compare contraceptive choice by HIV
status) but it may also suffer from reverse causality bias because
contraceptive choice is an important determinant of HIV status.
However, the ﬁndings based on the sample including both HIV-
infected and HIV-uninfected women are essentially the same as
TABLE 3. Effects of Progression Through the HIV Treatment Cascade on Contraception: Bivariate Probit Regression Coefﬁcients
Effects
Single Protection Single-Method Dual Protection
Coefﬁcient 95% CI P Coefﬁcient 95% CI P
Stage in the HIV treatment cascade
HIV+, unaware of HIV status 1 1
HIV+, awareness of HIV status unknown 20.138 20.623 to 0.348 0.578 0.410 0.014 to 0.806 0.042
HIV+, aware of HIV status 0.149 20.011 to 0.308 0.068 0.244 0.092 to 0.396 0.002
Pre-ART 0.161 20.011 to 0.333 0.067 0.135 20.034 to 0.305 0.117
0–1 years on ART 0.080 20.152 to 0.313 0.499 0.439 0.214 to 0.665 ,0.001
1–2 years on ART 0.233 20.014 to 0.480 0.064 0.425 0.178 to 0.671 0.001
2–4 years on ART 20.032 20.263 to 0.199 0.785 0.827 0.602 to 1.051 ,0.001
4–7 years on ART 0.103 20.179 to 0.385 0.475 0.903 0.623 to 1.183 ,0.001
Age 0.072 0.021 to 0.124 0.006 0.084 0.033 to 0.134 0.001
Age squared 20.001 20.002 to 0.000 0.012 20.002 20.002 to 20.001 ,0.001
Education 0.023 0.002 to 0.043 0.032 0.014 20.006 to 0.034 0.164
Married or in a marriage-like relationship 0.059 20.061 to 0.179 0.335 20.026 20.144 to 0.093 0.671
Pregnant 20.481 20.782 to 0.180 0.002 20.036 20.327 to 0.255 0.809
Parity 0.051 20.006 to 0.108 0.082 20.085 20.146 to 20.023 0.007
Health
Poor health 1 1
Fair health 20.091 20.602 to 0.420 0.726 0.180 20.369 to 0.729 0.520
Good health 20.089 20.630 to 0.451 0.746 0.045 20.527 to 0.616 0.878
Very good health 20.050 20.554 to 0.454 0.847 0.217 20.325 to 0.758 0.432
Excellent health 20.404 20.953 to 0.146 0.150 0.312 20.254 to 0.878 0.280
Household wealth quintile
Poorest 1 1
Second 0.050 20.102 to 0.202 0.520 20.025 20.175 to 0.124 0.740
Third 0.034 20.119 to 0.187 0.659 0.009 20.140 to 0.158 0.908
Fourth 0.045 20.110 to 0.200 0.571 20.056 20.210 to 0.097 0.472
Wealthiest 20.105 20.270 to 0.060 0.213 0.107 20.053 to 0.267 0.189
Distance to nearest major road 0.002 20.006 to 0.009 0.676 20.012 20.020 to 20.004 0.003
Distance to nearest secondary road 0.000 20.044 to 0.043 0.991 0.007 20.036 to 0.050 0.747
Calendar year
2005 1 1
2006 20.182 20.708 to 0.343 0.496 0.495 0.059 to 0.931 0.026
2007 20.220 20.754 to 0.315 0.421 0.635 0.195 to 1.074 0.005
2008 20.637 21.305 to 0.030 0.061 0.936 0.442 to 1.430 ,0.001
2009 0.606 0.056 to 1.156 0.031 0.497 0.030 to 0.965 0.037
2010 0.473 20.068 to 1.015 0.087 0.647 0.193 to 1.102 0.005
2011 0.450 20.088 to 0.987 0.101 0.704 0.255 to 1.153 0.002
2012 0.538 20.001 to 1.076 0.050 0.475 0.023 to 0.928 0.040
Sample size 3169
r = 20.292, x2 = 80.96, P , 0.0001
CI = conﬁdence interval; P = p value; ART = antiretroviral treatment; HIV+ = HIV-infected.
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No Contraception Single Protection
AME (in pp) 95% CI P AME (in pp) 95% CI P
Stage in the HIV treatment cascade
HIV+, unaware of HIV status Ref Ref
HIV+ awareness unknown 20.078 20.206 to 0.049 0.228 20.064 20.164 to 0.036 0.207
HIV+, aware of HIV status 20.094 20.140 to 20.047 ,0.001 0.012 20.028 to 0.052 0.558
Pre-ART 20.070 20.122 to 20.019 0.008 0.025 20.020 to 0.070 0.273
0–1 years on ART 20.129 20.195 to 20.063 ,0.001 20.026 20.081 to 0.029 0.352
1–2 years on ART 20.156 20.225 to 20.086 ,0.001 0.006 20.057 to 0.069 0.858
2–4 years on ART 20.212 20.273 to 20.151 ,0.001 20.088 20.134 to 20.043 ,0.001
4–7 years on ART 20.249 20.318 to 20.180 ,0.001 20.079 20.136 to 20.021 0.007
Age 20.037 20.052 to 20.021 ,0.001 0.009 20.004 to 0.022 0.177
Age squared 0.001 0.000 to 0.001 ,0.001 0.000 0.000 to 0.000 0.366
Education 20.009 20.015 to 20.002 0.007 0.004 20.001 to 0.009 0.147
Married or in a marriage-like relationship 20.007 20.044 to 0.029 0.689 0.016 20.015 to 0.047 0.316
Pregnant 0.110 0.020 to 0.200 0.016 20.098 20.156 to 20.041 0.001
Parity 0.009 20.009 to 0.027 0.332 0.019 0.004 to 0.034 0.012
Health status
Poor health Ref Ref
Fair health 20.025 20.190 to 0.139 0.761 20.035 20.159 to 0.088 0.575
Good health 0.009 20.164 to 0.182 0.919 20.024 20.156 to 0.108 0.724
Very good health 20.041 20.203 to 0.120 0.616 20.029 20.162 to 0.103 0.665
Excellent health 20.003 20.181 to 0.174 0.970 20.104 20.210 to 0.001 0.053
Household wealth quintile
Wealth quintile 1 Ref Ref
Wealth quintile 2 20.005 20.051 to 0.040 0.815 0.014 20.026 to 0.053 0.493
Wealth quintile 3 20.010 20.056 to 0.036 0.666 0.007 20.032 to 0.046 0.718
Wealth quintile 4 0.003 20.044 to 0.050 0.892 0.015 20.025 to 0.055 0.461
Wealth quintile 5 20.004 20.053 to 0.046 0.885 20.032 20.072 to 0.007 0.111
Distance to nearest primary road 0.002 0.000– to 0.005 0.039 0.001 20.001 to 0.003 0.161
Distance to nearest secondary road 20.002 20.015 to 0.012 0.806 20.001 20.012 to 0.010 0.904
Calendar year
2005 Ref Ref
2006 20.093 20.230 to 0.044 0.185 20.08 20.183 to 0.024 0.131
2007 20.125 20.260 to 0.009 0.068 20.098 20.195 to 0.000 0.049
2008 20.170 20.319 to 20.021 0.025 20.167 20.238 to 20.096 ,0.001
2009 20.244 20.371 to 20.117 ,0.001 0.070 20.068 to 0.208 0.323
2010 20.252 20.377 to 20.128 ,0.001 0.026 20.099 to 0.151 0.680
2011 20.265 20.392 to 20.138 ,0.001 0.022 20.100 to 0.144 0.725
2012 20.232 20.365 to 20.098 0.001 0.069 20.063 to 0.200 0.305
Sample size 3169
Single-Method Dual Protection Dual-Method Dual Protection
AME (in pp) 95% CI P AME (in pp) 95% CI P
Stage in the HIV treatment cascade
HIV+, unaware of HIV status Ref Ref
HIV+ awareness unknown 0.121 20.005 to 0.246 0.059 0.022 20.042 to 0.086 0.498
HIV+, aware of HIV status 0.046 0.005– to 0.088 0.030 0.035 0.014– to 0.056 0.001
Pre-ART 0.019 20.028 to 0.065 0.431 0.027 0.004– to 0.049 0.021
0–1 years on ART 0.103 0.034 to 0.172 0.003 0.052 0.014 to 0.089 0.007
1–2 years on ART 0.079 0.006 to 0.152 0.034 0.071 0.027 to 0.115 0.002
2–4 years on ART 0.222 0.150 to 0.294 ,0.001 0.078 0.037 to 0.120 ,0.001
4–7 years on ART 0.216 0.126 to 0.306 ,0.001 0.112 0.053 to 0.171 ,0.001
Age 0.014 0.000 to 0.027 0.046 0.014 0.008 to 0.020 ,0.001
(continued on next page)
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women. The ﬁndings from the multiply imputed analysis are
also similar to those of the main analysis, suggesting that the
missing data do not cause signiﬁcant bias. Finally, changes in
the coding and functional forms of the explanatory variables did
not lead to any signiﬁcant changes in the results. We present
these additional ﬁndings in the online Appendix (see Supple-
mental Digital Content, http://links.lww.com/QAI/A576),
where we also describe and interpret how the other explanatory
variables affected contraceptive choice.
DISCUSSION
We examine for the ﬁrst time the effect of progression
through the HIV treatment cascade on contraceptive use.
Among HIV-infected women, dually protective methods of
contraception can prevent unintended pregnancies, HIV
transmission, and the acquisition of other STIs. In a poor,
rural community in KwaZulu-Natal, South Africa, we ﬁnd
that both overall contraceptive use and dual-protection
contraception increased signiﬁcantly as HIV-infected women
moved from earlier to later stages in the treatment cascade.
Descriptively, the probability of contraception increased
from ,40% among HIV-infected women who did not know
their status to .70% among HIV-infected women 4–7y e a r so n
ART. Controlling for a wide range of potential confounders of
the relationship between the stages of the treatment cascade and
contraceptive use, we ﬁnd that progression through the cascade
signiﬁcantly increased the overall probability of contraception as
well as single- and dual-method dual protection.
Although signiﬁcant increases in dual protection
occurred across the entire cascade, these increases were
substantially larger after ART initiation compared with the
stages in the cascade when women learnt of their HIV status
or were enrolled in pre-ART care. The large ART-associated
increases are plausible based on several mechanisms. First, in
preparation for ART women receive intensive counseling,
including on methods to prevent transmission of HIV to
sexual partners. Second, women on ART are likely to discuss
their contraceptive behaviors and fertility intentions with
ART health workers during the routine ART follow-up visits.
Health workers should routinely initiate such discussions,
because based on the South African national ART guide-
lines
18 the ART regimen needs to be changed when a woman
TABLE 4. (Continued) Effects of Progression Through the HIV Treatment Cascade on Contraception: AME
Single-Method Dual Protection Dual-Method Dual Protection
AME (in pp) 95% CI P AME (in pp) 95% CI P
Age squared 0.000 20.001 to 0.000 0.007 0.000 0.000 to 0.000 ,0.001
Education 0.001 20.004 to 0.007 0.598 0.003 0.001 to 0.006 0.007
Married or in a marriage-like relationship 20.011 20.043 to 0.020 0.487 0.003 20.011 to 0.017 0.695
Pregnant 0.023 20.061 to 0.107 0.589 20.035 20.056 to 20.014 0.001
Parity 20.025 20.041 to 20.008 0.003 20.003 20.010 to 0.004 0.396
Health status
Poor health Ref Ref
Fair health 0.054 20.101 to 0.209 0.496 0.007 20.057 to 0.071 0.828
Good health 0.019 20.139 to 0.177 0.816 20.004 20.066 to 0.058 0.903
Very good health 0.057 20.082 to 0.196 0.423 0.014 20.042 to 0.070 0.634
Excellent health 0.119 20.057 to 0.296 0.184 20.012 20.068 to 0.045 0.689
Household wealth quintile
Wealth quintile 1 Ref Ref
Wealth quintile 2 20.010 20.050 to 0.030 0.610 0.002 20.016 to 0.020 0.817
Wealth quintile 3 20.001 20.041 to 0.040 0.970 0.004 20.014 to 0.021 0.686
Wealth quintile 4 20.017 20.058 to 0.023 0.400 20.001 20.019 to 0.017 0.913
Wealth quintile 5 0.036 20.010 to 0.082 0.121 0.000 20.019 to 0.019 0.990
Distance to nearest primary road 20.003 20.005 to 20.001 0.005 20.001 20.002 to 0.000 0.050
Distance to nearest secondary road 0.002 20.010 to 0.013 0.771 0.001 20.004 to 0.006 0.813
Calendar year
2005 Ref Ref
2006 0.148 0.010 to 0.286 0.035 0.024 20.046 to 0.095 0.502
2007 0.192 0.049 to 0.334 0.008 0.032 20.044 to 0.107 0.413
2008 0.336 0.169 to 0.503 ,0.001 0.001 20.073 to 0.075 0.976
2009 0.037 20.097 to 0.172 0.588 0.137 0.025 to 0.249 0.017
2010 0.095 20.040 to 0.230 0.169 0.131 0.028 to 0.235 0.013
2011 0.118 20.012 to 0.248 0.075 0.125 0.032 to 0.218 0.008
2012 0.053 20.074 to 0.180 0.414 0.110 0.019 to 0.201 0.018
Sample size 3169
CI, conﬁdence interval; Ref, reference category; P = p value; AME = average marginal effects; ART = antiretroviral treatment; HIV+ = HIV-infected.
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tion. These discussions offer repeated opportunities for edu-
cation on the beneﬁts of contraception with condoms. Third,
the ART clinics in this community provide male and female
condoms free of charge, so that ART clinic visits imply
access to dually protective contraceptives. It is possible that
the availability of free condoms in the ART program is a rea-
son for the larger increases observed in single-method dual
protection than in dual-method dual protection. Last, the ART
clinics are located on the premises of the primary-care clinics
and thus in close proximity to family planning and reproduc-
tive health services, where contraception information and
condoms are available. Future research needs to elucidate
whether information and counseling or condom availability
is responsible for the large effect of ART on dual protection
observed in this study. It will also be important to explore
whether more intensive counseling and increased condom
availability in HIV testing centers and pre-ART clinic visits
could increase use of dually protective methods early in the
HIV treatment cascade.
Our results have several important implications for policy
and research. First, the ART effects on contraception with
condoms could enhance biological treatment-as-prevention
effects.
13,23 The effects of progression through the HIV cascade
found here could also counteract increased sexual risk taking
among HIV-uninfected populations in response to ART scale-
up. Such “risk compensation”
34 behavior has been hypothe-
sized because the availability of ART decreases both the risk
of contracting HIV through unprotected sex as well as the
expected health losses after contracting HIV. However, the
evidence on “risk compensation” and its potential consequen-
ces for HIV incidence is weak, and it is possible that counter-
acting factors, such as ART-associated behavior change in
HIV-infected people has prevented its manifestation.
Second, despite the signiﬁcant and large increases in dual
protection across the HIV treatment cascade, in all cascade
stages large proportions of HIV-infected women continued
using only single-protection contraception. Although there are
signiﬁcant effects of learning about one’s positive HIV status
on both overall contraceptive use and contraception with con-
doms, these effects are small compared with the effects of
ART. Future intervention research is needed to determine
how HIV counseling and testing can be enhanced to achieve
larger dual-protection effects than currently.
Third, although dual-method dual protection increased as
women progressed through the HIV treatment cascade, these
increases were small relative to the increases in the use of
single-method dual protection, which is not as effective as
dual-method dual protection in preventing unintended preg-
nancy. Future research needs to establish what interventions—
for example, targeted provision of contraceptives, new types of
contraceptives, or stronger incentives to use contraceptives—
can lead to additional condom use among women who cur-
rently use other contraceptives and the addition of other contra-
ceptives among women who currently use condoms.
Our study has several strengths but it also has
important limitations. One strength of this study is that
information about contraception is elicited in the community
and not in patient interviews after HIV counseling or visits to
an ART clinic, where previous studies have elicited this
information.
35239 Although we cannot rule out social desir-
ability biases, such biases seem much less likely when ques-
tions about contraception are asked in patients’ homes and as
part of an interview on a wide range of issues rather than in
clinics after patients have just been counseled on a range of
ART-related issues, including on prevention of HIV trans-
mission. Home-based interviews are removed from the social
norm-setting context associated with ART and HIV counsel-
ing. Additionally, unlike in patient interviews, the ﬁeld-
workers conducting home-based interviews are unaware of
the HIV status of their interviewees; social norms related to
HIV status are thus unlikely to affect responses.
FIGURE 1. Progression through the
HIV treatment cascade and contra-
ceptive use.
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size and the fact that we could here for the ﬁrst time directly
compare the effects of different important stages across the
HIV treatment cascade, including gaining HIV status
knowledge, pre-ART, and ART initiation. An important
limitation is that we cannot rule out that unobserved
confounders have biased the observed relationships between
the stages of the cascade and contraceptive choice. One
important unobserved factor that could have confounded our
results is fertility intention. Fertility intention may decrease
when a woman learns about her positive HIV status;
35,36 in
this case, the estimated effect of HIV awareness on contra-
ceptive choice found in this study may be an overestimate of
the true effect. Conversely, fertility intentions may increase
after ART initiation as a woman’s health and future outlook
improves;
37–39 in this case, the effects of ART on contracep-
tion and dual protection found in this study may be under-
estimates of the true effects. Follow-up studies need to
establish causal effects more ﬁrmly. Because we cannot
randomly assign individuals to different stages in the cas-
cade, quasi-experimental studies will be the only option to
strengthen causal inference about the effects of the cascade
on contraceptive choice. Examples of quasi-experimental
approaches that could be feasible for this purpose include
instrumental variable approaches (using, for instance, dis-
tance to the nearest ART clinic as an instrument for ART
initiation) or regression discontinuity designs using the fact
that ART is initiated in patients by applying a threshold rule
to the continuous variable CD4 count.
40,41
CONCLUSIONS
Progression through the HIV treatment cascade signif-
icantly increased the likelihood of contraception in general
and contraception with condoms in particular. The largest
increases in contraception with condoms occurred after ART
initiation. Future integration of HIV and reproductive health
services can build on these achievements to further increase
the use of dual-protection contraception, especially in the
early stages of the HIV treatment cascade. Our results further
suggest that ART programs contribute to HIV prevention
through the behavioral pathway of changing contraception
uptake and choice.
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